Cargando…

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs

BACKGROUND: In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual b/tsDMARDs costs and disease outcomes in Norwegian rheumatoid arthritis (RA) patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brkic, Alen, Diamantopoulos, Andreas P., Haavardsholm, Espen Andre, Fevang, Bjørg Tilde Svanes, Brekke, Lene Kristin, Loli, Liz, Zettel, Camilla, Rødevand, Erik, Bakland, Gunnstein, Mielnik, Pawel, Haugeberg, Glenn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743354/ https://www.ncbi.nlm.nih.gov/pubmed/35012522 http://dx.doi.org/10.1186/s12913-021-07425-w

Ejemplares similares

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)
por: Brkic, Alen, et al.
Publicado: (2023)

Factors predicting death and cancer in patients with giant cell arteritis in Western Norway 1972–2012: a retrospective observational cohort study
por: Brekke, Lene Kristin, et al.
Publicado: (2023)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
por: Haaversen, Anne Bull, et al.
Publicado: (2023)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Differential sensitivity of the 2020 revised comprehensive diagnostic criteria and the 2019 ACR/EULAR classification criteria across IgG4-related disease phenotypes: results from a Norwegian cohort
por: Vikse, Jens, et al.
Publicado: (2023)

Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
por: Mielnik, Pawel, et al.
Publicado: (2023)

Cardiovascular disease risk profiles in inflammatory joint disease entities
por: Wibetoe, Grunde, et al.
Publicado: (2017)

Decentralizing healthcare in Norway to improve patient-centered outpatient clinic management of rheumatoid arthritis – a conceptual model
por: Brkic, Alen, et al.
Publicado: (2021)

The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy
por: Jonsson, Maria Karolina, et al.
Publicado: (2018)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review
por: Sahbudin, Ilfita, et al.
Publicado: (2023)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Risk factors for revision after shoulder arthroplasty: 1,825 shoulder arthroplasties from the Norwegian Arthroplasty Register
por: Fevang, Bjørg-Tilde S, et al.
Publicado: (2009)

Drug costs in context: assessing drug costs in cost-of-illness analyses
por: Mattingly, T Joseph, et al.
Publicado: (2022)

Remission or Not Remission, That’s the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis
por: Brkic, Alen, et al.
Publicado: (2022)

Improved results of primary total hip replacement: Results from the Norwegian Arthroplasty Register, 1987–2007
por: Fevang, Bjørg-Tilde S, et al.
Publicado: (2010)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

The Cost of Drugs
Publicado: (1905)

The Cost of Drugs
Publicado: (1905)

The Cost-Effectiveness of and Adherence to Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis Patients in a Tertiary Care Teaching Hospital in Uttarakhand, India
por: Mittal, Gauri, et al.
Publicado: (2023)

Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis
por: Dubash, Sayam R, et al.
Publicado: (2021)

Drug tendering: drug supply and shortage implications for the uptake of biosimilars
por: Dranitsaris, George, et al.
Publicado: (2017)

Good function after shoulder arthroplasty: 1,107 patients with 4 different diagnoses from the Norwegian Arthroplasty Register
por: Fevang, Bjørg-Tilde S, et al.
Publicado: (2012)

Frequency and trends of disease‐modifying antirheumatic drug (DMARD) use in Germany
por: Fassmer, Alexander M., et al.
Publicado: (2016)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis
por: Nossent, Johannes C., et al.
Publicado: (2019)

IL-1A gene variation in relation to cytokine levels and clinical characteristics in ankylosing spondylitis
por: Nossent, Johannes C., et al.
Publicado: (2019)

IL23R gene variants in relation to IL17A levels and clinical phenotype in patients with ankylosing spondylitis
por: Nossent, Johannes C, et al.
Publicado: (2018)

The Cost of Drugs to Hospitals
Publicado: (1905)

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial
por: Haavardsholm, Espen A, et al.
Publicado: (2016)

Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach
por: Aga, Anna-Birgitte, et al.
Publicado: (2016)

Survival and death causes of patients with giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study
por: Brekke, L. K., et al.
Publicado: (2019)

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
por: Peterson, Jeffrey D, et al.
Publicado: (2010)

Obesity Increases Disease Activity of Norwegian Patients with Axial Spondyloarthritis: Results from the European Map of Axial Spondyloarthritis Survey
por: Bindesbøll, Christian, et al.
Publicado: (2020)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
por: Malaviya, Anshuman P, et al.
Publicado: (2012)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
por: Pasma, Annelieke, et al.
Publicado: (2017)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p6j78omnggqgj8fd0i69c2ki53